Cardiac Safety Study of Brentuximab Vedotin (SGN-35) (NCT01026233)
The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (also known as SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.
- Hodgkin Disease
- Anaplastic Large-Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (NHL)
- Phase: I
- Enrollment: 52
- Start: January 2010
- Completion: August 2011
- Last verified: December 2014
Last Editorial review: July 10, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.